Insulin Resistance and Lipid Accumulation Product in Corelation to Body Mass Index in Women with Polycystic Ovary Syndrome
Amina Godinjak, Zulfo Godinjak, Azra Burekovic, Ismana Surkovic, Amela Dizdarevic-Bostandzic, Zelija Velija-Asimi
Med Arh. 2012; 66(6): 409-411
Introduction: Women with Polycystic Ovary Syndrome (PCOS) are at increased risk for cardiovascular morbidity and metabolic disorders including: dyslipidaemia, hypertension, insulin resistance, gestational diabetes, type 2 diabetes, systemic inflammation and endothelial dysfunction. The prevalence of obesity and insulin resistance in women with PCOS is significantly higher compared to the general population. Lipid accumulation product is a new, cheap and easily available predictor for metabolic syndrome both in general population and in women with PCOS. Materials and methods: The study included 50 patients at the Clinic of Endocrinology, Diabetes and Metabolic Disorders, Clinical Center University of Sarajevo. All patients were diagnosed with PCOS according to the Rotterdam ESHRE criteria and were divided into two groups according to their body mass index (BMI). A prospective study established the following parameters: anthropometric measurements (waist circumference, height, weight), BMI, and serum triglycerides and insulin resistance. LAP was calculated using the formula: LAP (women) = [waist circumference (cm)–58] × [triglycerides (mmol/L)]. Results: Waist circumference in women with BMI ≤ 24.9 kg/m2 was 31 cm lower than waist circumference in women with a BMI > 25 kg/m2. Mean triglyceride value of the patients in group BMI ≤ 24.9 kg/m2 was 1.15 mmol/l lower than the mean value of triglycerides in women with a BMI >25 kg/m2. Insulin resistance was present in 66.7% in group with BMI ≤ 24.9 kg/m2, and in 75.0% in the group with BMI>25.0 kg/m2. LAP was shown to be a marker for the differentiation of insulin–resistant and nonresistant patients with a cut-off value of 17.91. Conclusion: Patients with PCOS and BMI ≤ 24.9 kg/m2 were significantly different from those with BMI>25 kg/m2 in the values of body weight, waist circumference and triglycerides. There was no statistically significant difference in insulin resistance. LAP values were higher in patients in the group with BMI > 25 kg/m2. LAP was a marker for differentiation of insulin – resistant and non-resistant women with PCOS.
1. Dahlgren E, Janson PO, Johansson S, Lapidus I, Oden A. Polycystic ovary syndrome and risk for myocardial infarction. Acta Obstet Gynecol Scand. 1992; 71: 599-604.
2. Wiltgen D, Benedetto IG, Mastella LS, Spritzer PM. Lipid accumulation product index: a reliable marker of cardiovascular risk in polycystic ovary syndrome. Hum Reprod. 2009; 24(7): 1726-1731.
3. Kahn S, Valdez R. Metabolic risks identified by the combination of enlarged waist and elevated triacylglycerol concentration American Journal of Clinical Nutrition. 2003; 78(5): 928-934.
4. Taverna MJ, Martínez–Larrad MT, Frechtel GD, Serrano-Ríos M. Lipid accumulation product: a powerful marker of metabolic syndrome in healthy population. Eur J Endocrinol. 2011; 164(4): 559-567.
5. Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. AM J Med. 2001; 11(8): 607-613
6. Robinson S, Henderson AD, Gelding SV, Kiddy D, Niththyananthan R. Dyslipidaemia is associated with insulin resistance in women with polycystic ovaries. Clin Endocrinol (Oxf). 1996; 44(3): 277-284.
7. Hoeger KM, Oberfield SE. Do women with PCOS have a unique predisposition to obesity? Fertil Steril. 2012; 97(1): 13-17.
8. Kauffman RP, Baker TE, Graves-Evenson K, Baker VM, Castracane VD. Lipoprotein profiles in Mexican American and non-Hispanic white women with polycystic ovary syndrome. Fertil Steril. 2011; 96 (6): 1503-1507.
9. Pontes A.G. et al. Insulin resistance in women with polycystic ovary syndrome: relationship with anthropometric and biochemical variables. Rev. Bras. Ginecol. Obstet. 2012; 10: 36-43.
10. Sarapatková H, Hrcková Y, Sarapatková R. Basic anthropometric characteristics and their relationship with the metabolism of saccharides in women with PCOS. Ceska Gynekol. 2011; 76 (5): 343-348.
11. Karabulut A, Yaylali GF, Demirlenk S, Sevket O, Acun A. Evaluation of body fat distribution in PCOS and its association with carotid atherosclerosis and insulin resistance.Gynecol Endocrinol. 2012; 28(2):111-114.
12. Kim JW, Han JE, Kim YS, Won HJ, Yoon TK. High sensitivity C-reactive protein and its relationship with impaired glucose regulation in lean patients with polycystic ovary syndrome. Gynecol Endocrinol. 2011; 16(9): 51-65.
13. Wehr E, Gruber HJ, Giuliani A, Möller R, Pieber TR. The lipid accumulation product is associated with impaired glucose tolerance in PCOS women. J Clin Endocrinol Metab. 2011; 96(6): 986-990.